Dexmedetomidine Hydrochloride is a small molecule that works as Adrenergic Receptor Alpha-2 Agonist.[2] It is being investigated across 8 indications, with its most advanced program in Phase 3.[1]
Dexmedetomidine Hydrochloride is one of 118 small molecule programs targeting Septic Shock. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
78 competitors in Delirium
Precedex
Exelon
Rozerem
Seroquel
Aleve
Voltaren
Duragesic
Anerem
Spravato
Belsomra
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources